Web Exclusives

NEJM: Perspective on foodborne diseases

The Feb. 23 issue of The New England Journal of Medicine (NEJM) includes a perspective on foodborne disease. Read it at http://www.nejm.org/doi/full/10.1056/NEJMp1010907.

FDA approves new drug for lupus

The U.S. Food and Drug Administration has approved Benlysta (belimumab) for treatment of lupus. The FDA last approved a drug for lupus in 1955.…

FDA approves new drug for COPD

The U.S. Food and Drug Administration has approved roflumilast, an oral drug that reduces exacerbations from severe chronic obstructive pulmonary disease (COPD). Read more…

Fidaxomicin reduces C. diff recurrence

Compared to vancomycin, patients treated with fidaxomicin for Clostridium difficile infection were significantly less likely to have a recurrence. Read more here.

NEJM: Perspective on foodborne diseases

The Feb. 23 issue of The New England Journal of Medicine (NEJM) includes a perspective on foodborne disease. Read it at http://www.nejm.org/doi/full/10.1056/NEJMp1010907.

FDA approves new drug for lupus

The U.S. Food and Drug Administration has approved Benlysta (belimumab) for treatment of lupus. The FDA last approved a drug for lupus…

FDA approves new drug for COPD

The U.S. Food and Drug Administration has approved roflumilast, an oral drug that reduces exacerbations from severe chronic obstructive pulmonary disease (COPD).…

Fidaxomicin reduces C. diff recurrence

Compared to vancomycin, patients treated with fidaxomicin for Clostridium difficile infection were significantly less likely to have a recurrence. Read more here.

Test Your Knowledge

Emotional Intel TYK

In what way does emotional intelligence affect nursing leaders in team and patient care settings?

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • This field is hidden when viewing the form

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.